¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Somatic cell and molecular genetics."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • islet cell adenoma
    ¼¶¼¼Æ÷»ùÁ¾
  • islet cell carcinoma
    ¼¶¼¼Æ÷¾ÏÁ¾
  • immunologically competent cell
    ¸é¿ª¼¼Æ÷
  • indeterminate cell
    ºÎÁ¤Çü¼¼Æ÷
  • indifferent cell
    ¹«°ü¼¼Æ÷
  • inducer cell
    À¯µµ¼¼Æ÷
  • inflammatory cell
    ¿°Áõ¼¼Æ÷
  • infundibular cell
    ±ò¶§±â¼¼Æ÷, ´©µÎ¼¼Æ÷
  • inner cell mass
    ¼Ó¼¼Æ÷µ¢ÀÌ, ³»¼¼Æ÷±«
  • intercalated cell
    »çÀ̼¼Æ÷, °³Àç¼¼Æ÷
  • interdental cell
    û°¢Ä¡¾Æ»çÀ̼¼Æ÷, Ä¡°£¼¼Æ÷
  • intermediate cell mass
    Áß°£¼¼Æ÷µ¢ÀÌ, Áß°£¼¼Æ÷±«
  • interstitial cell
    »çÀÌÁú¼¼Æ÷, °£Áú¼¼Æ÷
  • interstitial cell-stimulating hormone
    »çÀÌÁú¼¼Æ÷ÀÚ±ØÈ£¸£¸ó, °£Áú¼¼Æ÷ÀÚ±ØÈ£¸£¸ó
  • interstitial plasma cell pneumonia
    »çÀÌÁúÇüÁú¼¼Æ÷Æó·Å, ÆóÆ÷ÀÚÃæÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • luteal cell
    Ȳü¼¼Æ÷
  • lymphoid cell
    ¸²ÇÁ°è¼¼Æ÷, ¸²ÇÁ¸ð¾ç¼¼Æ÷
  • lymphokine-activated killer cell
    ¸²Æ÷Ä«ÀÎȰ¼º¼¼Æ÷µ¶¼º¼¼Æ÷
  • lymphopoietic cell
    ¸²ÇÁ±¸»ý¼º¼¼Æ÷
  • marrow cell
    °ñ¼ö¼¼Æ÷
  • mast cell
    ºñ¸¸¼¼Æ÷
  • mastoid air cell
    ²ÀÁö¹úÁý
  • matrix cell
    ±âÁú¼¼Æ÷, ÅйÙÅÁÁú¼¼Æ÷
  • memory cell
    ¸é¿ª±â¾ï¼¼Æ÷
  • Merkel cell-neurite complex
    Ã˰¢¼¼Æ÷½Å°æµ¹±âº¹ÇÕü
  • mesangial cell
    Ç÷°ü»çÀ̼¼Æ÷
  • mesenchymal cell
    Áß°£¿±¼¼Æ÷
  • mesothelial cell
    ÁßÇǼ¼Æ÷
  • microglial cell
    ¹Ì¼¼¾Æ±³¼¼Æ÷
  • mitotic cell
    ºÐ¿­±â¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • horny cell
    °¢Áú¼¼Æ÷
  • huma immunodeficiency virus,follicular dendritic cell infection by
    ¿©Æ÷»ó¼öÁö¼¼Æ÷°¨¿°
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T-cell lymphotrophic virus
    Àΰ£ T¼¼Æ÷ ¸²ÇÁ ¿µ¾ç¼º ¹ÙÀÌ·¯½º
  • human t-cell leukemia virus
    ÀÎü T¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • hybrid cell
    ÇÏÀ̺긮µå¼¼Æ÷
  • hybridoma, B cell
    B¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
  • hybridoma, T cell
    T¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
  • hypercomplex cell
    Ãʺ¹ÇÕ¼¼Æ÷(õ±ÜÜùêá¬øà)
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
  • hypersensitivity reactions,type iv(cell-mediated)
    IVÇü
  • hypersensitivity, cell-mediated
    ¼¼Æ÷¸Å°³ °ú¹Î¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • stress and coping model
    ½ºÆ®·¹½º¿Í ´ëó(Óßô¥)¸ðµ¨.
  • suck and snout reflex
    ÀԴٽñâ¹Ý»ç, »¡°íÇÓ ±â¹Ý»ç.
  • superficial (skin and mucous membrane
    Ç¥Àç(ÇǺΠ¹× Á¡¸·)¹Ý»ç.
  • superficial and deep parotid lymph nodes
    ¾è°í±íÀº±Í¹Ø»ù¸²ÇÁÀý, õ½ÉÀÌÇϼ±(ô¼ä¢ì¼?ÇØºÎ,À̺ñ
  • syndrome of neonatal fever, rash, and arthropathy
  • synovial bursae and sheaths
    À±È°ÁÖ¸Ó´Ï ¹× À±È°Áý
  • tendon sheath of abductor longus and extenor brevis
    ±ä¾öÁö¹ú¸²±Ù°úªÀº¾öÁöÆï±ÙÈûÁÙ
  • tendon sheath of extensor digitorum and extensor indicis
    ¼Õ°¡¶ôÆï±Ù°úÁý°ÔÆï±ÙÈûÁÙÁý
  • tentorial and subfacial herniation
    õ¸·ÀýÈçÅ»Ãâ ¹× ´ë³ú°âÇÏÅ»Ãâ
  • thoracostomy and underwater seal drainge
    Èä°­»ð°ü ¹× ¼öºÀ½Ä¹è¾×¹ý.
  • thyroidal protease and peptidase
    °©»ó¼±´Ü¹éºÐÇØÈ¿¼Ò(¡­Ó±ÛÜÝÂú°ý£áÈ).
  • time, dose and fractionation factor, TDF factor
    ½Ã°£¼±·®ºÐÇÒÀÎÀÚ
  • to and fro absorbent system
    ¿Õº¹Èí¼ö¹ý.
  • to and fro anesthesia apparatus
    ¿Õº¹½Ä¸¶Ãë±â(èÙÜÖãÒØ«ö­Ðï).
  • to and fro flow
    ÀüÈÄÀ¯µ¿.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 20
HTC hepatoma cell; hepatoma tissue culture; homozygous typing cell
HTLV-MA cell membrane antigen associated with the human T-cell leukemia virus
ISC immunoglobulin-secreting cells; insoluble collagen; International Society of Cardiology; Internation...
JGCT juvenile granulosa cell tumor; juxtaglomerular cell tumor
K cell killer cell
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 20
BMD Bone mineral content and density
BMC Bone mineral density and content
BI-RADS Breast Imaging Reporting And Data System
BAL Bronchoscopy and bronchoalveolar lavage
BuCy Busulfan and cyclophosphamide
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • heterotrophic cell
    Á¾¼Ó ¿µ¾ç ¼¼Æ÷
    ¿µ¾ç¿øÀ¸·Î¼­ À¯±â¹°À» ÇÊ¿ä·Î ÇÏ´Â ¼¼Æ÷.
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human t-cell leukemia virus
    ÀÎü T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • Hurthle cell
    Hurthle ¼¼Æ÷
    dzºÎÇÑ ¼¼Æ÷Áú³» ¸¹Àº È£»ê¼º °ú¸³À» ÇÔÀ¯.
  • huthle cell adenoma
    ÈÖ¸£Æ®·¹ ¼¼Æ÷ ¼±Á¾, Huthle ¼¼Æ÷ ¼±Á¾
  • hypercomplex cell
    Ãʺ¹ÇÕ ¼¼Æ÷
  • hypoxic cell sensitizer
    Àú»ê¼Ò ¼¼Æ÷ °¨ÀÛÁ¦
  • immunocompetent foreign lymphoid cell
    ¿ÜºÎ ¸é¿ªÀû°Ý ÀÓÆÄ°è ¼¼Æ÷
  • immunologically committed cell
    ¸é¿ª °æÇè ¼¼Æ÷
  • immunologically performing cell
    ¸é¿ª ¼öÇà ¼¼Æ÷
  • inflammatory cell infiltration
    ¿°Áõ ¼¼Æ÷ÀÇ Ä§À±
    ¿°ÁõÀ» ÀÏÀ¸Å°¸é »ýü´Â ¹æ¾îÀûÀ¸·Î Ȱµ¿ÇÏ°í ¿°Áõ ¹°ÁúÀÇ Á¦°Å, ¿°ÁõÀÇ ÁøÀüÀ» ÀúÁöÇϱâ À§ÇØ ÁÖ·Î Ç÷¾×ÁßÀÇ ¹éÇ÷±¸
  • inhibitory output cell
    ¾ïÁ¦ Ãâ·Â ¼¼Æ÷
  • inhibitory substantia gelatinosa cell
    ¾ïÁ¦¼º ±³¾çÁú ¼¼Æ÷
  • interkinetic cell :

    interlabial

    ÀÔ¼ú »çÀÌÀÇ
  • intermediate cell
    Áß°£ ¼¼Æ÷
    ÁßÃþ ÆíÆò »óÇÇ Á¶Á÷ÀÇ Áß°£Ãþ, ÁÖ·Î °ú¸³ ¼¼Æ÷ÃþÀ» Â÷ÁöÇÏ´Â ¼¼Æ÷·Î¼­ ¼¼ Æ÷Áø¿¡¼­´Â Ç¥Ãþ ¼¼Æ÷º¸´Ù ¾à°£ ÀÛ¾Æ 30-50 ¸¶ÀÌÅ©·Î¹ÌÅÍÀÇ ´Ù°¢ÇüÀ̳ª À¯¿øÇüÀÇ ¿¯Àº ¼¼Æ÷ÁúÀ» Áö´Ñ ÆíÆòÇÑ ¼¼Æ÷. ÇÙÀº ¼¼Æ÷ÀÇ Á߽ɿ¡ ÀÖÀ¸¸ç, Ç¥Ãþ ¼¼Æ÷º¸´Ù´Â ¾à°£ Å©°í, ¼ÒÆ÷»óÀÇ ÇÙ³» ±¸Á¶¸¦ °üÂûÇÒ ¼ö ÀÖ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
sprains and strains A collective term for muscle and ligament injuries without dislocation or fracture. A sprain is a joint injury in which some of the fibres of a supporting ligament are ruptured but the continuity of the ligament remains intact. A strain is an overstretching or overexertion of some part of the musculature.
(12 Dec 1998)
national institute for occupational safety and health An institute of the centres for disease control and prevention which is responsible for assuring safe and healthful working conditions and for developing standards of safety and health. Research activities are carried out pertinent to these goals.
(12 Dec 1998)
standards and guidelines Bounds or constraints within which all practices in a given area will be carried out, in achieving the goals and objectives for that area. Standards and guidelines provide environmental safeguards and also describe constraints prescribed by law.
(05 Dec 1998)
nebulisers and vaporisers Devices that cause a liquid or solid to be converted into an aerosol (spray) or a vapor. It is used in drug administration by inhalation, humidification of ambient air, and in certain analytical instruments.
(12 Dec 1998)
state health planning and development agencies Agencies established under pl93-641 to coordinate, conduct, and implement state health planning activities. Two primary responsibilities are the preparation of an annual state health plan and giving assistance to the statewide health coordinating council.
(12 Dec 1998)
stem and loop structure <molecular biology> The structure of tRNAs is so termed because it has four base paired stems and three loops (not base paired), one of which contains the anticodon.
(18 Nov 1997)
neonatal diseases and abnormalities Diseases existing at birth and often before birth, regardless of causation. Of these congenital diseases, those characterised by structural deformities are termed abnormalities.
(12 Dec 1998)
neoplasms, adnexal and skin appendage Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
(12 Dec 1998)
neoplasms, complex and mixed Neoplasms composed of more than one type of neoplastic tissue.
(12 Dec 1998)
neoplasms, connective and soft tissue Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
(12 Dec 1998)
neoplasms, cystic, mucinous, and serous Neoplasms containing cyst-like formations or producing mucin or serum.
(12 Dec 1998)
neoplasms, ductal, lobular, and medullary Neoplasms, usually carcinoma, located within the centre of an organ or within small lobes, and in the case of the breast, intraductally. The emphasis of the name is on the location of the neoplastic tissue rather than on its histological type. most cancers of this type are located in the breast.
(12 Dec 1998)
neoplasms, glandular and epithelial Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
(12 Dec 1998)
nephelometry and turbidimetry Chemical analysis based on the phenomenon whereby light, passing through a medium with dispersed particles of a different refractive index from that of the medium, is attenuated in intensity by scattering. In turbidimetry, the intensity of light transmitted through the medium, the unscattered light, is measured. In nephelometry, the intensity of the scattered light is measured, usually, but not necessarily, at right angles to the incident light beam.
(12 Dec 1998)
neuropathies, hereditary motor and sensory A group of slowly progressive inherited disorders in which the predominant involvement is the peripheral motor neurons with lesser involvement of the peripheral sensory neurons. Neuronal degeneration and atrophy are characteristic of these disorders. Some of the associated characteristics are phytanic acid excess, optic atrophy, and retinitis pigmentosa.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 20
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 20
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 20
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 20
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 20
ÅëÇÕ°Ë»ö ¿Ï·á